Form 4: JNJ Director Mary C. Beckerle Receives Deferred Share Units
Statement of Changes in Beneficial Ownership
Johnson & Johnson director Mary C. Beckerle acquired 975 deferred share units as part of the company's director compensation plan.
Summary
- Director Mary C. Beckerle was granted 975 Deferred Share Units (DSUs) on April 23, 2026.
- The DSUs were acquired under the Johnson & Johnson Amended and Restated Deferred Fee Plan for Directors.
- These units are to be settled in cash upon the termination of the director's service.
- The total number of DSUs held by the director following this transaction is 16,797.7393, which includes accrued dividend equivalent rights.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative event, as it represents standard director compensation rather than a strategic shift or market-moving event.
Positives
- The transaction reflects standard director compensation practices aligned with long-term equity retention.
- The inclusion of dividend equivalent rights demonstrates the accumulation of value for the director over time.
Negatives
- None identified; this is a routine administrative filing regarding director compensation.
Risks
- The value of the deferred share units is tied to the future market performance of Johnson & Johnson common stock.
Future Outlook
The filing does not provide forward-looking financial guidance, as it is a routine disclosure of director equity compensation.
Industry Context
StockSavvy.ai notes that this filing is a standard regulatory disclosure for large-cap pharmaceutical companies, reflecting typical corporate governance and director compensation structures within the S&P 500.
Comparison to Industry Standards
- The use of Deferred Share Units for director compensation is a standard practice among major healthcare peers such as Pfizer, Merck, and Eli Lilly to align director interests with long-term shareholder value.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation | Grant of Deferred Share Units under the Amended and Restated Deferred Fee Plan for Directors. | 2026-04-23 | Neutral; standard alignment of director interests with company performance. |
Stakeholder Impact
- Minimal impact on shareholders as this is a routine compensation disclosure.
Next Steps
- The director will continue to hold these units until the termination of her directorship.
Key Dates
| Date | Description |
|---|---|
| 2025-12-04 | Date of Power of Attorney execution for SEC filings. |
| 2026-04-23 | Date of the transaction involving the grant of Deferred Share Units. |
| 2026-04-27 | Date of the filing of the Form 4. |
Keywords
Johnson & Johnson, JNJ, Director Compensation, Deferred Share Units, SEC Form 4, Insider Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.